GCP
TCRT icon

GSA Capital Partners’s Alaunos Therapeutics TCRT Stock Holding History

GSA Capital Partners’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,797
Closed -$75K – 1918
2023
Q3 		$75K Sell
3,797
-6,082
-62% -$262K 0.01% 1401
2023
Q2 		$756K Buy
9,879
+2,526
+34% +$204K 0.08% 473
2023
Q1 		$695K Buy
7,353
+971
+15% +$92.5K 0.07% 512
2022
Q4 		$621K Buy
6,382
+2,328
+57% +$337K 0.08% 467
2022
Q3 		$1.05M Sell
4,054
-2,207
-35% -$641K 0.14% 136
2022
Q2 		$1.17M Buy
6,261
+4,711
+304% +$450K 0.17% 95
2022
Q1 		$152K Buy
+1,550
New +$199K 0.02% 1231
2017
Q2 		– Sell
-71
Closed -$67K – 1944
2017
Q1 		$67K Buy
+71
New +$66.1K ﹤0.01% 1684
2016
Q2 		– Sell
-319
Closed -$355K – 1904
2016
Q1 		$355K Buy
319
+202
+173% +$207K 0.02% 1212
2015
Q4 		$146K Buy
117
+43
+58% +$71.1K 0.01% 1698
2015
Q3 		$100K Sell
74
-55
-43% -$90.8K ﹤0.01% 1656
2015
Q2 		$233K Buy
+129
New +$200K 0.01% 1750

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCA
Magnolia Capital Advisors Jackson, Mississippi $509M AUM 18.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

GSA Capital Partners's TCRT Position: Q4 2023 in Review

GSA Capital Partners sold out of Alaunos Therapeutics (TCRT) in Q4 2023, closing a stake of 3,797 shares — an estimated $75K sold.

GSA Capital Partners first reported a position in TCRT in Q2 2015 and held it in 12 quarters. The position peaked at $1.17M in Q2 2022. 82 funds tracked by Wall St. Rank hold TCRT as of Q4 2023.

  • GSA Capital Partners reported no remaining Alaunos Therapeutics position as of Q4 2023 after selling out during the quarter.
  • GSA Capital Partners sold 3,797 Alaunos Therapeutics shares in Q4 2023, an estimated $75K.
  • GSA Capital Partners first reported a position in Alaunos Therapeutics in Q2 2015 and held it in 12 quarters.
  • GSA Capital Partners's Alaunos Therapeutics position peaked at $1.17M in Q2 2022.
  • 82 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2023.

Based on GSA Capital Partners's 13F filing for Q4 2023, filed 16 Feb 2024.